Related Experiment Video
Updated: Jul 17, 2026
12:17
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
[Aortic valve replacement with a Cryolife O'Brien stentless bioprosthesis]
Vicente Campos1, Belén Adrio, Francisco Estévez
1Servicio de Cirugía Cardiaca, Hospital Universitario Juan Canalejo, A Coruña, Spain. vcampos@ya.com
Revista Espanola De Cardiologia
|February 10, 2007
Summary
The Cryolife O'Brien stentless bioprosthesis showed good short-term results in aortic valve replacement. Echocardiography confirmed improved valve function and reduced cardiac strain one year post-surgery.
Area of Science:
- Cardiovascular Surgery
- Bioprosthetic Devices
- Cardiac Valve Replacement
Background:
- The Cryolife O'Brien xenograft is a stentless bioprosthesis made from porcine aortic valve leaflets.
- Aortic valve replacement is a common procedure for treating aortic valve disease.
Purpose of the Study:
- To evaluate the short-term outcomes of aortic valve replacement using the Cryolife O'Brien stentless bioprosthesis.
Main Methods:
- A cohort of 210 patients received the Cryolife O'Brien bioprosthesis between October 1993 and 12 months postoperatively.
- Patient demographics and indications for surgery (aortic stenosis, insufficiency, or both) were recorded.
- Echocardiography was used to assess valve function, including gradients and effective area, as well as left ventricular mass and thickness at multiple time points.
Main Results:
- The 30-day mortality rate was 5.2%.
- Significant improvements in valve function were observed, with decreased mean gradients and increased effective area index.
- Reductions in left ventricular mass index, wall thickness, and septum thickness were noted post-surgery.
Conclusions:
- The Cryolife O'Brien stentless bioprosthesis demonstrated satisfactory short-term performance up to 1-year follow-up.
- Long-term follow-up is necessary to fully assess the durability and performance of this bioprosthesis.
More Related Videos
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...